• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2019冠状病毒病疫苗研发现状：聚焦抗原设计及后期临床试验

Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages.

作者信息

Lee Pureum, Kim Chang-Ung, Seo Sang Hawn, Kim Doo-Jin

机构信息

Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea.

Department of Bioscience, University of Science and Technology (UST), Daejeon 34113, Korea.

出版信息

Immune Netw. 2021 Feb 26;21(1):e4. doi: 10.4110/in.2021.21.e4. eCollection 2021 Feb.

DOI:10.4110/in.2021.21.e4
PMID:33728097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7937514/
Abstract

The global outbreak of coronavirus disease 2019 (COVID-19) is still threatening human health, economy, and social life worldwide. As a counteraction for this devastating disease, a number of vaccines are being developed with unprecedented speed combined with new technologies. As COVID-19 vaccines are being developed in the absence of a licensed human coronavirus vaccine, there remain further questions regarding the long-term efficacy and safety of the vaccines, as well as immunological mechanisms in depth. This review article discusses the current status of COVID-19 vaccine development, mainly focusing on antigen design, clinical trials in later stages, and immunological considerations for further study.

摘要

2019年冠状病毒病（COVID-19）的全球大流行仍在威胁着全球人类健康、经济和社会生活。作为应对这种毁灭性疾病的措施，多种疫苗正以前所未有的速度结合新技术进行研发。由于COVID-19疫苗是在尚无获得许可的人类冠状病毒疫苗的情况下研发的，因此关于疫苗的长期有效性和安全性以及深入的免疫机制仍存在进一步的问题。这篇综述文章讨论了COVID-19疫苗研发的现状，主要关注抗原设计、后期临床试验以及有待进一步研究的免疫学考量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c0/7937514/e1d47e6bcebe/in-21-e4-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c0/7937514/4add13e1030a/in-21-e4-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c0/7937514/c46bab9d830d/in-21-e4-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c0/7937514/0d1f5431ff95/in-21-e4-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c0/7937514/e1d47e6bcebe/in-21-e4-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c0/7937514/4add13e1030a/in-21-e4-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c0/7937514/c46bab9d830d/in-21-e4-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c0/7937514/0d1f5431ff95/in-21-e4-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c0/7937514/e1d47e6bcebe/in-21-e4-g004.jpg

相似文献

1
Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages.2019冠状病毒病疫苗研发现状：聚焦抗原设计及后期临床试验
Immune Netw. 2021 Feb 26;21(1):e4. doi: 10.4110/in.2021.21.e4. eCollection 2021 Feb.
2
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.CEPI/BC 2020 年 3 月 12-13 日会议共识总结报告：评估 COVID-19 疫苗引起疾病增强的风险。
Vaccine. 2020 Jun 26;38(31):4783-4791. doi: 10.1016/j.vaccine.2020.05.064. Epub 2020 May 25.
3
COVID-19 vaccines: concerns beyond protective efficacy and safety.COVID-19 疫苗：除了保护效力和安全性之外的关注点。
Expert Rev Vaccines. 2021 Aug;20(8):1013-1025. doi: 10.1080/14760584.2021.1949293. Epub 2021 Jul 5.
4
Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after T2-biased immunization.T2 偏向性免疫接种后 COVID-19 仓鼠疫苗相关增强的呼吸病理学。
Cell Rep. 2022 Aug 16;40(7):111214. doi: 10.1016/j.celrep.2022.111214. Epub 2022 Aug 3.
5
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.新冠疫苗的快速研发和早期成功为加速癌症治疗机制带来了希望。
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.
6
Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).2019年冠状病毒病（COVID-19）当前疫苗研发策略综述
Toxicol Pathol. 2020 Oct;48(7):800-809. doi: 10.1177/0192623320959090. Epub 2020 Sep 14.
7
A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.《COVID-19 疫苗研发的进展与挑战综述》。
Front Immunol. 2020 Oct 14;11:585354. doi: 10.3389/fimmu.2020.585354. eCollection 2020.
8
COVID-19 Vaccine: A comprehensive status report.新型冠状病毒肺炎疫苗：全面现状报告。
Virus Res. 2020 Oct 15;288:198114. doi: 10.1016/j.virusres.2020.198114. Epub 2020 Aug 13.
9
Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms.应对 COVID-19 疫苗设计的基本考虑因素和开创性疫苗候选平台的综述。
Int Immunopharmacol. 2021 Aug;97:107679. doi: 10.1016/j.intimp.2021.107679. Epub 2021 Apr 15.
10
The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans.COVID-19 疫苗接种之旅：对当前人体临床试验的全面系统综述。
Panminerva Med. 2022 Mar;64(1):72-79. doi: 10.23736/S0031-0808.20.03958-0. Epub 2020 May 26.

引用本文的文献

1
Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity.基于工程细胞外囊泡的疫苗平台的开发，用于联合递送 mRNA 和蛋白质以诱导功能性免疫。
J Control Release. 2024 Oct;374:550-562. doi: 10.1016/j.jconrel.2024.08.017. Epub 2024 Aug 30.
2
SARS-CoV-2 spike RBD-specific IgA and IgG antibodies in breast milk after vaccination with the protein subunit vaccine Abdala.接种蛋白亚单位疫苗阿夫达拉后母乳中针对SARS-CoV-2刺突RBD的IgA和IgG抗体
Infect Med (Beijing). 2022 Dec;1(4):253-261. doi: 10.1016/j.imj.2022.11.001. Epub 2022 Nov 18.
3

本文引用的文献

1
Preclinical study of a DNA vaccine targeting SARS-CoV-2.针对 SARS-CoV-2 的 DNA 疫苗的临床前研究。
Curr Res Transl Med. 2022 Sep;70(4):103348. doi: 10.1016/j.retram.2022.103348. Epub 2022 Apr 20.
2
Preexisting memory CD4 T cells in naïve individuals confer robust immunity upon hepatitis B vaccination.在未感染个体中，预先存在的记忆性 CD4 T 细胞赋予其对乙型肝炎疫苗接种的强大免疫力。
Elife. 2022 Jan 25;11:e68388. doi: 10.7554/eLife.68388.
3
Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model.
Sequential Administration of SARS-CoV-2 Strains-Based Vaccines Effectively Induces Potent Immune Responses against Previously Unexposed Omicron Strain.
基于SARS-CoV-2毒株的疫苗序贯接种可有效诱导针对此前未接触过的奥密克戎毒株的强效免疫反应。
Pathogens. 2023 Apr 28;12(5):655. doi: 10.3390/pathogens12050655.
4
A Comprehensive Review on Various Aspects of SARS-CoV-2 (COVID-19) Vaccines.关于严重急性呼吸综合征冠状病毒2（COVID-19）疫苗各方面的综合综述
Int J Prev Med. 2022 Nov 28;13:151. doi: 10.4103/ijpvm.ijpvm_513_21. eCollection 2022.
5
Evaluation of the analytical performance of three chemiluminescence serological assays for detecting anti-SARS-CoV-2 antibodies.三种化学发光血清学检测方法用于检测抗 SARS-CoV-2 抗体的分析性能评估。
Clin Exp Med. 2023 Aug;23(4):1205-1211. doi: 10.1007/s10238-022-00918-w. Epub 2022 Oct 19.
6
A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines.SARS-CoV-1 与 SARS-CoV2 的比较：当前 COVID-19 疫苗的最新进展。
Daru. 2022 Dec;30(2):379-406. doi: 10.1007/s40199-022-00446-8. Epub 2022 Sep 2.
7
mRNA vaccines in the prevention and treatment of diseases.信使核糖核酸疫苗在疾病预防和治疗中的应用
MedComm (2020). 2022 Aug 25;3(3):e167. doi: 10.1002/mco2.167. eCollection 2022 Sep.
8
Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin.新型冠状病毒肺炎疫苗ChAdOx1-S和BNT162b2与凝血因子及抗凝血酶循环水平的关联
Vaccines (Basel). 2022 Jul 31;10(8):1226. doi: 10.3390/vaccines10081226.
9
Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects.COVID-19 疫苗：免疫原性、当前研发进展和未来前景的系统评价。
Front Immunol. 2022 Apr 27;13:843928. doi: 10.3389/fimmu.2022.843928. eCollection 2022.
10
Scope of SARS-CoV-2 variants, mutations, and vaccine technologies.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体、突变及疫苗技术的范围
Egypt J Intern Med. 2022;34(1):34. doi: 10.1186/s43162-022-00121-z. Epub 2022 Mar 26.
皮内递送 DNA 疫苗可诱导持久免疫，介导恒河猴 SARS-CoV-2 挑战模型中病毒载量的降低。
Cell Rep Med. 2021 Oct 19;2(10):100420. doi: 10.1016/j.xcrm.2021.100420. Epub 2021 Sep 28.
4
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents.基于信使核糖核酸的严重急性呼吸综合征冠状病毒2候选疫苗CVnCoV可诱导高水平的病毒中和抗体并在啮齿动物中发挥保护作用。
NPJ Vaccines. 2021 Apr 16;6(1):57. doi: 10.1038/s41541-021-00311-w.
5
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.INO-4800新冠DNA疫苗的安全性和免疫原性：一项开放标签1期临床试验的初步报告
EClinicalMedicine. 2021 Jan;31:100689. doi: 10.1016/j.eclinm.2020.100689. Epub 2020 Dec 24.
6
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
7
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.一项关于加强型 ChAdOx1 nCoV-19 疫苗的 SARS-CoV-2 疫苗的 1/2 期临床试验可诱导多功能抗体反应。
Nat Med. 2021 Feb;27(2):279-288. doi: 10.1038/s41591-020-01179-4. Epub 2020 Dec 17.
8
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
9
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
10
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.一项在 18-59 岁健康成年人中进行的新型冠状病毒灭活疫苗的安全性、耐受性和免疫原性的随机、双盲、安慰剂对照、1/2 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17.